Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments

Nuclear factor erythroid 2-related factor 2 (Nrf2) is involved in tumor drug resistance, but its role in imatinib resistance of chronic myeloid leukemia (CML) remains elusive. We aimed to investigate the effects of Nrf2 on drug sensitivity, thioredoxin reductase (TrxR) expression, reactive oxygen sp...

Full description

Bibliographic Details
Main Authors:	Lianrong Xu, Yan Zhao, Fei Pan, Mengxia Zhu, Liqin Yao, Yan Liu, Jiangfang Feng, Jie Xiong, Xiuhua Chen, Fanggang Ren, Yanhong Tan, Hongwei Wang
Format:	Article
Language:	English
Published:	Hindawi Limited 2019-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2019/6502793

Similar Items

To inhibit TrxR1 is to inactivate STAT3–Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors
by: Sander Busker, et al.
Published: (2020-09-01)

MiR-23-TrxR1 as a novel molecular axis in skeletal muscle differentiation
by: Neri Mercatelli, et al.
Published: (2017-08-01)

Changes of 8-OHdG and TrxR in the Residents Who Bathe in Radon Hot Springs
by: Gao Yanxiao, et al.
Published: (2019-01-01)

Selenocysteine induces apoptosis in human glioma cells: evidence for TrxR1-targeted inhibition and signaling crosstalk
by: Cun-dong Fan, et al.
Published: (2017-07-01)

GSK-3beta Inhibitor Induces Expression of Nrf2/TrxR2 Signaling Pathway to Protect against Renal Ischemia/Reperfusion Injury in Diabetic Rats
by: Bo Hu, et al.
Published: (2016-12-01)

Licochalcone a Induces ROS-Mediated Apoptosis through TrxR1 Inactivation in Colorectal Cancer Cells
by: Peng Wu, et al.
Published: (2020-01-01)

Novel TrxR1 Inhibitors Show Potential for Glioma Treatment by Suppressing the Invasion and Sensitizing Glioma Cells to Chemotherapy
by: Mirna Jovanović, et al.
Published: (2020-10-01)

Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer
by: Haiyong Zhang, et al.
Published: (2021-08-01)

Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells
by: Rossana Galassi, et al.
Published: (2021-01-01)

Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells
by: Wei He, et al.
Published: (2019-05-01)

Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells
by: Xi Chen, et al.
Published: (2019-02-01)

Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
by: Qianqian Zhang, et al.
Published: (2019-10-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011-03-01)

miR-125a Suppresses TrxR1 Expression and Is Involved in H2O2-Induced Oxidative Stress in Endothelial Cells
by: Fangjie Chen, et al.
Published: (2018-01-01)

A possible role for selenoprotein glutathione peroxidase (GPx1) and thioredoxin reductases (TrxR1) in thyroid cancer: our experience in thyroid surgery
by: Alessio Metere, et al.
Published: (2018-01-01)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01)

TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
by: Mateja Grat, et al.
Published: (2004-12-01)

Calcitonin receptor gene expression in K562 chronic myelogenous leukemic cells
by: Pondel Marc D, et al.
Published: (2003-04-01)

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells
by: Alphy Rose James, et al.
Published: (2017-02-01)

Allylated Curcumin Analog CA6 Inhibits TrxR1 and Leads to ROS-Dependent Apoptotic Cell Death in Gastric Cancer Through Akt-FoxO3a
by: Rajamanickam V, et al.
Published: (2020-01-01)

The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
by: Camillo Porta, et al.
Published: (2011-12-01)

Investigation of the mechanism of resistance to imatinib in chronic myelogenous leukemia at middle Taiwan
by: Chan-Yarn, et al.

Efeitos do chumbo sobre a atividade da tioredoxina redutase citosólica (TrxR1) e parâmetros de estresse oxidativo em rins de ratos.
by: Conterato, Greicy Michelle Marafiga
Published: (2012)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
by: Katerina Arvaniti, et al.
Published: (2014-07-01)

Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells.
by: Huey-Lan Huang, et al.
Published: (2011-01-01)

The role of CD69 in the cell fate of chronic myelogenous leukemia cell line K562
by: Jung-Chen Li, et al.
Published: (2006)

Investigating anti-tumoral activity of adenine on human chronic myelogenous leukemia cell K-562
by: I-Yin Chen, et al.
Published: (2016)

Prodigiosin induced the caspase-dependent apoptosis in human chronic myelogenous leukemia K562 cell
by: Maryam Niakani, et al.
Published: (2021-01-01)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01)

Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells
by: Shi D, et al.
Published: (2016-11-01)

Assesment Of The Efficacy Of HESA-A On The Proliferation And Apoptosis Of Chronic Myelogenous Leukemia Cell Line(K562)
by: Mahdihe Ghasemi, et al.
Published: (2012-12-01)

Assesment Of The Efficacy Of HESA-A On The Proliferation And Apoptosis Of Chronic Myelogenous Leukemia Cell Line(K562)
by: Mahdihe Ghasemi, et al.
Published: (2012-11-01)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
by: Scheid Christoph, et al.
Published: (2011-05-01)

Nucleostemin depletion induces post-G1 arrest apoptosis in chronic myelogenous leukemia K562 cells
by: Negin Gogani, et al.
Published: (2014-03-01)

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy
by: Ćojbašić Irena, et al.
Published: (2010-01-01)

Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
by: Jaroslav Jelinek, et al.
Published: (2011-01-01)

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
by: Viviana De Rosa, et al.
Published: (2019-06-01)